Three-Pronged attack on rectal cancer before surgery
NCT ID NCT05731726
Summary
This study is testing a combination of three treatments given before surgery for locally advanced rectal cancer. The goal is to see if adding an immunotherapy drug (serplulimab) and an anti-inflammatory drug (celecoxib) to standard chemotherapy (CAPEOX) can shrink tumors more effectively. Researchers hope this approach will lead to better surgical outcomes and lower the chance of the cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital School of Medicine Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.